Q-omics provides the consensus-scored PYCARD profile across patient tissues and cancer cell-line models. PYCARD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PYCARD is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PYCARD protein abundance shows 21,312 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where PYCARD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PYCARD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PYCARD survival associations across molecular data types. PYCARD RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PYCARD RNA expression–survival associations across cancer types. High PYCARD expression shows unfavorable associations in KIRC, LAML, LGG and UCS, but favorable associations in UVM and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PYCARD RNA expression.
This table summarizes PYCARD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PYCARD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PYCARD shows lower tumor expression in LUAD and higher tumor expression in KIRC, THCA, HNSC, KIRP and STAD. The KIRC box plot shows higher PYCARD RNA expression in tumor versus normal tissue (log2 FC = +2.262, t-test p < 0.001).
This table shows molecular features associated with PYCARD in patient tissues and cancer cell lines. In patient samples, PYCARD shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PYCARD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
